

WIKINGO Project Systematic Analysis

Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

Contents

List of Tables

1	Participant characteristics	3
2	According to Local Recurrence	4
3	According to Metastasis	6
4	According to Exitus	8
5	Incidence by outcome [95% CI]	13

List of Figures

1	Local Recurrence	5
2	Metastasis	7
3	Exitus	9
4	Local Recurrence, according to Type of Resection:	10
5	Metastasis, according to Type of Resection:	11
6	Survival, according to Type of Resection:	12

Table 1: Participant characteristics

	[ALL] N=225	N
Age	66.2 (11.6)	225
Sex: Men	159 (70.7%)	225
Tumor level:		225
0-6cm	87 (38.7%)	
7-12cm	104 (46.2%)	
13-15cm	34 (15.1%)	
Tumor stage:		225
0	16 (7.11%)	
I	49 (21.8%)	
II	69 (30.7%)	
III	91 (40.4%)	
Neoadjuvant treatment	113 (50.2%)	225
Type of resection:		225
Abdominoperineal resection	64 (28.4%)	
Anterior resection	124 (55.1%)	
Hartmann	37 (16.4%)	
Perforation	27 (12.0%)	225
Invasion circumferential margin	29 (12.9%)	225
Mesorecto quality:		225
Satisfactory	152 (67.6%)	
Partial	47 (20.9%)	
No-satisfactory	26 (11.6%)	
Recidive	7 (3.11%)	225
Months to recidive	25.0 [6.00;40.0]	225
Metastasis	19 (8.44%)	225
Months to Metastasis	23.0 [5.00;39.0]	225
Exitus	39 (17.3%)	225
Months to exitus	25.0 [6.00;41.0]	225


Table 2: According to Local Recurrence

	No event n= 218	Event n= 7	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	6.63 (1.16)	6.26 (1.10)	0.83 [0.46;1.49]	0.531	0.64 [0.21; 1.93]	0.431
Sex: Men	155 (71.1%)	4 (57.1%)	0.49 [0.11;2.19]	0.350	0.08 [0.00; 2.05]	0.126
Tumor level:						
0-6cm	86 (39.4%)	1 (14.3%)	0.38 [0.02;6.09]	0.493	7.21 [0.19; 270.10]	0.285
7-12cm	99 (45.4%)	5 (71.4%)	1.58 [0.18;13.6]	0.676	0.76 [0.02; 35.41]	0.888
Tumor stage:						
0	15 (6.88%)	1 (14.3%)	173342462 [0.00;.]	0.998	228121662.39 [0.00; Inf]	0.994
II	68 (31.2%)	1 (14.3%)	41786034 [0.00;.]	0.998	8966614.31 [0.00; Inf]	0.995
III	86 (39.4%)	5 (71.4%)	166130567 [0.00;.]	0.998	3042449.11 [0.00; Inf]	0.995
Neoadjuvant treatment	111 (50.9%)	2 (28.6%)	0.38 [0.07;1.94]	0.242	0.01 [0.00; 1.11]	0.055
Type of resection:						
Abdominoperineal resection	64 (29.4%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0.00; Inf]	0.999
Hartmann	33 (15.1%)	4 (57.1%)	7.68 [1.70;34.6]	0.008	0.39 [0.01; 26.05]	0.662
Perforation	22 (10.1%)	5 (71.4%)	18.0 [3.48;92.8]	0.001	201.40 [2.60;15601.46]	0.017
Invasion circumferential margin	25 (11.5%)	4 (57.1%)	10.2 [2.25;46.4]	0.003	87.81 [0.79; 9732.73]	0.062
Mesorecto quality:						
Partial	45 (20.6%)	2 (28.6%)	2.33 [0.39;14.0]	0.353	0.13 [0.00; 4.26]	0.253
No-satisfactory	24 (11.0%)	2 (28.6%)	3.13 [0.52;18.8]	0.211	0.12 [0.00; 5.89]	0.283

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	225	152	113	73	35	14


Table 3: According to Metastasis

	No event n= 206	Event n= 19	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.66 (1.15)	6.12 (1.11)	0.76 [0.54;1.08]	0.126	0.77 [0.53; 1.12]	0.165	225
Sex: Men	146 (70.9%)	13 (68.4%)	0.81 [0.31;2.14]	0.675	0.82 [0.30; 2.24]	0.705	225
Tumor level:							225
0-6cm	78 (37.9%)	9 (47.4%)	1.17 [0.31;4.33]	0.818	0.59 [0.08; 4.11]	0.594	
7-12cm	97 (47.1%)	7 (36.8%)	0.66 [0.17;2.55]	0.547	0.45 [0.10; 1.93]	0.28	
Tumor stage:							225
0	16 (7.77%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.998	
II	65 (31.6%)	4 (21.1%)	0.73 [0.18;2.91]	0.652	0.90 [0.21; 3.77]	0.882	
III	80 (38.8%)	11 (57.9%)	1.53 [0.49;4.82]	0.464	2.38 [0.65; 8.69]	0.19	
Neoadjuvant treatment	101 (49.0%)	12 (63.2%)	1.66 [0.65;4.22]	0.286	1.40 [0.45; 4.40]	0.56	225
Type of resection:							225
Abdominoperineal resection	56 (27.2%)	8 (42.1%)	1.84 [0.71;4.79]	0.210	2.33 [0.48;11.35]	0.296	
Hartmann	35 (17.0%)	2 (10.5%)	1.03 [0.22;4.79]	0.967	0.91 [0.14; 5.97]	0.921	
Perforation	23 (11.2%)	4 (21.1%)	1.84 [0.61;5.55]	0.279	2.23 [0.46;10.80]	0.317	225
Invasion circumferential margin	26 (12.6%)	3 (15.8%)	1.13 [0.33;3.90]	0.842	0.52 [0.12; 2.35]	0.395	225
Mesorecto quality:							225
Partial	42 (20.4%)	5 (26.3%)	1.63 [0.57;4.70]	0.364	1.54 [0.47; 5.03]	0.478	
No-satisfactory	23 (11.2%)	3 (15.8%)	1.23 [0.34;4.41]	0.751	0.93 [0.18; 4.76]	0.933	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	225	150	103	65	31	13


Table 4: According to Exitus

	No event n= 186	Event n= 39	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.58 (1.16)	6.81 (1.13)	1.21 [0.92;1.60]	0.176	1.21 [0.90;1.63]	0.207	225
Sex: Men	137 (73.7%)	22 (56.4%)	0.48 [0.26;0.91]	0.024	0.43 [0.22;0.86]	0.016	225
Tumor level:							225
0-6cm	73 (39.2%)	14 (35.9%)	1.04 [0.40;2.71]	0.944	1.22 [0.35;4.27]	0.759	
7-12cm	85 (45.7%)	19 (48.7%)	1.08 [0.43;2.71]	0.877	0.86 [0.32;2.30]	0.763	
Tumor stage:							225
0	16 (8.60%)	0 (0.00%)	0.00 [0.00;.]	0.997	0.00 [0.00; Inf]	0.996	
II	58 (31.2%)	11 (28.2%)	0.99 [0.38;2.56]	0.984	1.09 [0.40;2.92]	0.868	
III	70 (37.6%)	21 (53.8%)	1.65 [0.70;3.88]	0.253	1.64 [0.65;4.13]	0.29	
Neoadjuvant treatment	96 (51.6%)	17 (43.6%)	0.79 [0.42;1.48]	0.457	1.03 [0.47;2.28]	0.937	225
Type of resection:							225
Abdominoperineal resection	55 (29.6%)	9 (23.1%)	0.97 [0.44;2.13]	0.938	0.84 [0.28;2.50]	0.757	
Hartmann	27 (14.5%)	10 (25.6%)	2.66 [1.23;5.73]	0.013	2.07 [0.76;5.62]	0.154	
Perforation	19 (10.2%)	8 (20.5%)	1.81 [0.83;3.95]	0.135	2.00 [0.68;5.91]	0.21	225
Invasion circumferential margin	21 (11.3%)	8 (20.5%)	1.96 [0.90;4.29]	0.092	0.92 [0.36;2.38]	0.865	225
Mesorecto quality:							225
Partial	34 (18.3%)	13 (33.3%)	1.97 [0.97;3.97]	0.060	1.61 [0.76;3.40]	0.214	
No-satisfactory	20 (10.8%)	6 (15.4%)	1.31 [0.52;3.27]	0.563	0.98 [0.34;2.80]	0.964	

Reference categories:


- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 3: Exitus




Months	0	12	24	36	48	60
N:	225	154	116	74	36	15

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	64	48	34	21	10	2
Ant	124	89	71	48	26	11
H	37	17	10	7	1	1

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	64	46	30	17	8	2
Ant	124	87	65	43	24	10
H	37	19	14	8	1	1

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	64	48	34	21	10	2
Ant	124	89	71	48	27	12
H	37	19	14	8	1	1

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	1.23 [2.91; 0]	2.93 [5.43; 0.36]	7.71 [11.41; 3.85]
24	3.98 [7.05; 0.8]	11.92 [17.15; 6.36]	13.76 [18.82; 8.39]
36	3.98 [7.05; 0.8]	13.06 [18.64; 7.09]	18.9 [25; 12.31]
48	5.45 [9.57; 1.15]	14.58 [20.75; 7.94]	25.97 [33.83; 17.17]
60	5.45 [9.57; 1.15]	14.58 [20.75; 7.94]	36.79 [48.02; 23.14]